Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | RAD52 | P43351 | 1/20 | 0.62 |
| ▸ | UBE2N | P61088 | 1/20 | 0.62 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.61 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.54 |
| ▸ | CCNC | P24863 | 3/20 | 0.53 |
| ▸ | CDK8 | P49336 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.48 |
| ▸ | LSS | P48449 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3961759 | 0.93 | SIGMAR1 (0.61) | L3MBTL1RAD52UBE2NMKNK1MKNK2 | |
| SCHEMBL7425708 | 0.90 | MKNK1 (0.72) | L3MBTL1MKNK1MKNK2SIGMAR1KCNH2 | |
| Trifluoroacetic Acid SCHEMBL15565817 | 0.83 | HPGD (0.63) | L3MBTL1RAD52UBE2NMKNK2SIGMAR1 | |
| SCHEMBL5273 | 0.83 | SIGMAR1 (0.70) | MKNK1MKNK2SIGMAR1HPGDCYP3A4 | |
| Trifluoroacetic Acid SCHEMBL27832857 | 0.82 | SIGMAR1 (0.81) | L3MBTL1RAD52UBE2NMKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL1597605 | 0.81 | SIGMAR1 (0.68) | MKNK1MKNK2SIGMAR1HPGDCYP3A4 | |
| SCHEMBL8260488 | 0.81 | SIGMAR1 (0.72) | L3MBTL1MKNK1MKNK2SIGMAR1CCNC | |
| Trifluoroacetic Acid SCHEMBL16150177 | 0.81 | SIGMAR1 (0.59) | L3MBTL1RAD52UBE2NMKNK1MKNK2 | |
| Trifluoroacetic Acid SCHEMBL7719722 | 0.78 | PDK1 (0.57) | L3MBTL1RAD52UBE2NMKNK1MKNK2 | |
| SCHEMBL5266293 | 0.78 | SIGMAR1 (0.80) | MKNK1MKNK2SIGMAR1CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1031563-B1 | SULFONYL DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| US-20030232808-A1 | Sulfonyl derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-12-18 | — | — | US | disclosed |
| US-6525042-B1 | Inhibits an activated coagulation factor FXa; anticoagulant, antithrombotic | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-02-25 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| EP-1031563-A1 | SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | L3MBTL1 274/4885RAD52 3785/4885UBE2N 2557/4885 |
| US-20030232808-A1 | Sulfonyl derivatives | SULT1E1, SULT2A1, SULT1A1 | L3MBTL1 776/4885RAD52 4789/4885UBE2N 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.